What are the indications, dosing recommendations, contraindications, and alternative therapies for doxepin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Doxepin: Clinical Overview

Doxepin is a tricyclic antidepressant indicated primarily for depression, anxiety, and insomnia, with low doses (3-6 mg) specifically FDA-approved for sleep maintenance insomnia and higher doses (75-300 mg) for depression and anxiety disorders. 1

Primary Indications

FDA-Approved Uses 1

Depression and Anxiety (Higher Doses):

  • Psychoneurotic patients with depression and/or anxiety
  • Depression/anxiety associated with alcoholism (not to be taken with alcohol)
  • Depression/anxiety associated with organic disease
  • Psychotic depressive disorders with associated anxiety, including involutional depression and manic-depressive disorders

Insomnia (Low Doses):

  • Sleep maintenance insomnia is the primary indication for low-dose doxepin (3 mg and 6 mg), with clinically significant improvements in wake after sleep onset (WASO), total sleep time (TST), and sleep efficiency. 2

Off-Label Uses

Pruritus Management:

  • Topical doxepin (5% cream) for generalized pruritus, limited to 8 days of use, maximum 10% body surface area, and 12 g daily due to contact dermatitis risk 3
  • Oral low-dose doxepin (10 mg three times daily) for pruritus associated with allergic cutaneous reactions when conventional antihistamines fail 4

Dosing Recommendations

For Depression/Anxiety 1

Initial Dosing:

  • Mild to moderate severity: Start 75 mg daily
  • Adjust at appropriate intervals based on response
  • Usual optimum range: 75-150 mg/day

Severe Illness:

  • May require higher doses with gradual increase to 300 mg/day maximum
  • Additional therapeutic effect rarely obtained beyond 300 mg/day

Mild Symptomatology:

  • May suffice with 25-50 mg/day

Administration:

  • Can be given as divided doses or once-daily (maximum 150 mg for once-daily dosing)
  • Once-daily dosing should be given at bedtime
  • The 150 mg capsule is for maintenance only, not treatment initiation

For Insomnia 2

Evidence-Based Dosing:

  • 3 mg or 6 mg nightly
  • Both doses show clinically significant improvements in WASO (22-23 min reduction vs placebo) and TST (26-32 min increase vs placebo)
  • 6 mg shows mild increase in somnolence compared to 3 mg
  • Minimal effect on sleep latency at either dose

For Pruritus 3, 4

Topical:

  • Apply to affected areas
  • Maximum 8 days duration
  • Maximum 10% body surface area
  • Maximum 12 g daily

Oral:

  • 10 mg three times daily for allergic cutaneous reactions

Special Population Considerations

Elderly Patients 1

  • Start on low doses and observe closely
  • More likely to have decreased renal function requiring dose adjustment
  • Sedating effects may cause confusion and oversedation
  • Elderly patients were successfully studied at 3-6 mg for insomnia 2

Pediatric Patients 1

  • Not recommended for children under 12 years due to lack of clinical experience
  • Case report of chronic toxicity in a 10-year-old at 4.41 mg/kg (300 mg) highlights significant risk 5

Pharmacogenomic Considerations 6, 7, 5

  • CYP2D6 and CYP2C19 polymorphisms cause significant interindividual variability
  • Blood level monitoring can optimize dosing in subtherapeutic responders
  • Age affects clearance (CL/F decreases with age)
  • Body weight affects volume of distribution
  • Therapeutic plasma level: 100-300 ng/mL combined doxepin-nordoxepin

Contraindications 1

Absolute Contraindications:

  • Hypersensitivity to doxepin or other dibenzoxepines
  • Glaucoma
  • Urinary retention tendency

Important Warnings:

  • Black Box Warning: Increased risk of suicidal thinking and behavior in children, adolescents, and young adults (ages 18-24) with major depressive disorder 1
  • Risk differences by age: <18 years (14 additional cases per 1000), 18-24 years (5 additional cases per 1000)
  • Adults ≥65 years show 6 fewer cases per 1000 compared to placebo

Drug Interactions and Precautions

Critical Interactions 1, 7, 5

  • CYP2D6 inhibitors (e.g., clobazam) and CYP2C19 inhibitors (e.g., topiramate) can precipitate toxicity
  • Co-medication inhibiting P450 isoenzymes lowers clearance by 15%
  • At doses >150 mg/day, may block antihypertensive effects of guanethidine and related compounds
  • Alcohol contraindicated when treating alcohol-associated depression

Monitoring Requirements 6

  • Blood level monitoring recommended for patients unresponsive to typical doses
  • Therapeutic range: 100-300 ng/mL (combined doxepin-nordoxepin)
  • Consider pharmacogenomic testing (CYP2D6, CYP2C19) for optimization

Adverse Effects

Common Side Effects 2, 1

Low-Dose (3-6 mg for insomnia):

  • Headache
  • Somnolence (mild increase at 6 mg)
  • Diarrhea
  • Upper respiratory infection

Higher Doses (Depression/Anxiety):

  • Drowsiness (most common, tends to disappear with continued therapy)
  • Anticholinergic effects: dry mouth, blurred vision, constipation, urinary retention
  • Cardiovascular: hypotension, hypertension, tachycardia
  • CNS: confusion, disorientation, hallucinations, ataxia, seizures
  • Hematologic: eosinophilia, rare bone marrow depression

Serious Adverse Events 1, 8, 5

  • Drug abuse potential identified in pharmacovigilance data 8
  • Chronic toxicity can mimic epilepsy with confusion, ataxia, and seizures 5
  • QRS prolongation on ECG indicates toxicity
  • Withdrawal symptoms possible with abrupt cessation after prolonged use

Alternative Therapies

For Sleep Maintenance Insomnia 2

Other Recommended Agents:

  • Eszopiclone (2-3 mg): TST improvement 28-57 min, WASO reduction 10-14 min, moderate-to-large sleep quality improvement
  • Suvorexant (10-20 mg): TST improvement 10 min, WASO reduction 16-28 min
  • Zolpidem (10 mg): TST improvement 29 min, WASO reduction 25 min, moderate sleep quality improvement
  • Temazepam (15 mg): TST improvement 99 min, small sleep quality improvement

For Depression/Anxiety 1

  • Other tricyclic antidepressants
  • SSRIs and SNRIs (preferred first-line in younger patients due to suicide risk profile)
  • Cognitive behavioral therapy for insomnia (CBT-I) as non-pharmacological option

Clinical Pearls and Pitfalls

Key Advantages:

  • Most potent H1 antihistamine receptor antagonist at low doses 9
  • Dual H1 and H2 blocking properties for pruritus 4
  • No physical tolerance or psychological dependence 1
  • Anti-anxiety effect appears before antidepressant effect (optimal antidepressant effect may take 2-3 weeks) 1

Common Pitfalls to Avoid:

  • Do not label treatment failures without considering blood level monitoring—inadequate dosing due to pharmacogenomic variability is common 6
  • Do not exceed 8 days for topical use due to contact dermatitis risk 3
  • Do not abruptly discontinue after prolonged use—taper gradually to avoid withdrawal symptoms 1
  • Do not overlook drug interactions with CYP2D6/2C19 inhibitors that can cause toxicity 5
  • Monitor for QRS prolongation on ECG as indicator of toxicity 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.